Furthermore, the phase III APPLE (WJOG11218L) clinical trial revealed that the incorporation of anti‐angiogenic agents into immune‐chemotherapy regimens resulted in an extended PFS for patients with EGFR‐mutated NSCLC after EGFR‐TKI failure (HR, 0.70; 95% CI, 0.46–1.06).19 This evidence concerns the gene EGFR and non-small cell lung carcinoma.